Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
about
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationDirect-acting antivirals for chronic hepatitis C.Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients.Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.Overcoming the resistance to resistance testing: Collecting the data.Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease.Direct-acting antivirals for chronic hepatitis CChallenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virusResistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionSafety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
P2860
Q28079102-009AB79F-6126-4F45-8C2C-149D85C38405Q34557595-7B30C27E-F960-4B71-AC33-4FC763051380Q38714156-12BA01D1-4F6D-48E5-BE79-E999C17E593AQ38779980-76428E06-6B8D-42DD-94C3-9DE0B5EF0A8CQ38824198-A6B70E43-6EB9-42C2-8738-9563913B8570Q38888859-9475731B-CCE6-481E-84B8-9B20F6CC39ADQ38893104-D92AF8EB-91D5-4C4B-B4AC-EF6BA642B215Q39092977-94CFDD00-4165-4AEE-BBD4-55FFB1BADEF8Q40052719-523A9AB7-F528-4A59-97B9-DB9C8E8F3D92Q40239514-39275A47-1866-483F-8D4E-6767CD37F872Q40337619-EECE230D-6A7E-485D-BEDB-E00F5B585A2BQ41632962-5566E953-2FE1-42C4-B671-274057CAC39DQ45324912-59F2AAAF-87A5-4EF9-AAFB-6AA3AAEB6F09Q45325504-A3845059-2C8C-413C-B9CF-94D864D0842AQ47549498-0BC8FC1F-A17D-4735-A96E-02D630E55951Q47572297-35B4BCBD-9A0F-457B-8430-3CF63BCF781FQ48329834-38B4CA85-61DE-4C17-85BE-47DE849E6BA3Q55065074-A2C7C8F1-8CCB-4958-9B60-F8C05A1A74BFQ55218109-86C7D547-EC92-45B1-B2A4-25510D74325DQ57389418-E354DDC8-66D3-478C-A4A2-DB949B6A795BQ57815119-34B81BBA-5780-4418-829A-7046AF4EBE52Q58697287-DD38DF7B-93F9-4091-BBFB-75BB3835E46EQ58763037-4E9B776C-BF00-4AF9-826A-05A18498A2F5
P2860
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@ast
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@en
type
label
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@ast
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@en
prefLabel
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@ast
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@en
P2093
P2860
P356
P1476
Susceptibilities of genotype 1 ...... o the NS5A inhibitor elbasvir.
@en
P2093
Anita Y M Howe
Mark J DiNubile
Patricia A Jumes
Patricia McMonagle
Paul Ingravallo
Stephanie Curry
Stephanie Kong
Steven W Ludmerer
P2860
P304
P356
10.1128/AAC.01390-15
P407
P577
2015-08-24T00:00:00Z